Johan W De Fijter
Overview
Explore the profile of Johan W De Fijter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
2873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bezstarosti S, Erpicum P, Maggipinto G, Dreyer G, Reinders M, Meziyerh S, et al.
Front Genet
. 2024 Oct;
15:1436194.
PMID: 39399215
Mesenchymal stromal cells (MSCs) have immunomodulatory properties and are therefore considered promising tools in kidney transplantation. Although most studies have been conducted with autologous MSCs, using allogeneic MSCs as an...
2.
de Rooij E, Hoogeveen E, Romijn F, van der Kooy S, Veighey K, Dekker F, et al.
Sci Rep
. 2024 Jun;
14(1):12901.
PMID: 38839764
Early kidney injury may be detected by urinary markers, such as beta-2 microglobulin (B2M), tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor-binding protein 7 (IGFBP7), kidney injury molecule-1 (KIM-1) and/or...
3.
Lengton R, Dekker F, van Rossum E, De Fijter J, Rosendaal F, Willems van Dijk K, et al.
Endocrine
. 2024 Apr;
85(3):1141-1153.
PMID: 38627329
Purpose: Obesity may promote kidney damage through hemodynamic and hormonal effects. We investigated the association between body mass index (BMI), total body fat (TBF) and chronic kidney disease (CKD) and...
4.
Zhai Q, Moes D, van Gelder T, van der Lee M, Sanders J, Bemelman F, et al.
Clin Transl Sci
. 2024 Feb;
17(2):e13729.
PMID: 38380703
CYP3A4 activity shows considerable interindividual variability. Although studies indicate 60%-80% is heritable, common single nucleotide variants (SNVs) in CYP3A4 together only explain ~10%. Transcriptional factors, such as the testis-specific Y-encoded-like...
5.
Kardol-Hoefnagel T, Senejohnny D, Kamburova E, Wisse B, Reteig L, Gruijters M, et al.
HLA
. 2024 Jan;
103(1):e15346.
PMID: 38239046
In kidney transplantation, survival rates are still partly impaired due to the deleterious effects of donor specific HLA antibodies (DSA). However, not all luminex-defined DSA appear to be clinically relevant....
6.
Kardol-Hoefnagel T, Senejohnny D, Kamburova E, Wisse B, Gruijters M, Joosten I, et al.
HLA
. 2024 Jan;
103(1):e15297.
PMID: 38226401
In kidney transplantation, donor HLA antibodies are a risk factor for graft loss. Accessibility of donor eplets for HLA antibodies is predicted by the ElliPro score. The clinical usefulness of...
7.
Dekker S, Bierau J, Giera M, Blomberg N, Drenth J, Mayboroda O, et al.
Eur J Clin Invest
. 2023 Dec;
54(4):e14147.
PMID: 38071418
Background: Polycystic liver disease (PLD) is a common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Bile acids may play a role in PLD pathogenesis. We performed a post-hoc...
8.
Dreyer G, Drabbels J, De Fijter J, van Kooten C, Reinders M, Heidt S
Front Immunol
. 2023 Nov;
14:1240347.
PMID: 38022634
Introduction: Mesenchymal stromal cell (MSC) therapy is a promising treatment that allows for drug minimization in clinical kidney transplantation. While it is thought that MSCs rapidly go into apoptosis after...
9.
van den Born J, Meziyerh S, Vart P, Bakker S, Berger S, Florquin S, et al.
Transplantation
. 2023 Aug;
108(2):556-566.
PMID: 37650722
Background: Evidence on the optimal maintenance of immunosuppressive regimen in kidney transplantation recipients is limited. Methods: The Amsterdam, LEiden, GROningen trial is a randomized, multicenter, investigator-driven, noninferiority, open-label trial in...
10.
van Duijl T, de Rooij E, Treep M, Koelemaij M, Romijn F, Hoogeveen E, et al.
Clin Chem
. 2023 Jul;
69(8):924-935.
PMID: 37477911
Background: We explored the potential of emerging and conventional urinary kidney injury biomarkers in recipients of living donor (LD) or donation after circulatory death (DCD) kidney transplantation, patients with chronic...